Rodolfo Abreu, João Monteiro e Castro, Frederico Bastos Gonçalves, Gonçalo Rodrigues, Anita Quintas, Rita Ferreira, Nelson Camacho, Maria Emília Ferreira, João Albuquerque e Castro, Luís Mota Capitão
{"title":"格拉斯哥动脉瘤评分作为腹主动脉瘤破裂患者死亡率预测模型的应用","authors":"Rodolfo Abreu, João Monteiro e Castro, Frederico Bastos Gonçalves, Gonçalo Rodrigues, Anita Quintas, Rita Ferreira, Nelson Camacho, Maria Emília Ferreira, João Albuquerque e Castro, Luís Mota Capitão","doi":"10.1016/j.ancv.2016.04.005","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>The updated Glasgow Aneurysm Score (uGAS), designed to predict mortality/morbidity perioperative after rAAA, proved to be a good predictor of short term results after treatment with conventional surgery (CC) and EVAR. The objectives were to characterize patients operated at rAAA and evaluate the applicability of uGAS in the population of a national tertiary institution with rEVAR capacity.</p></div><div><h3>Methods</h3><p>We did a retrospective analysis of patients operated in our service to rAAA between February/2011 to February/2015. The variables were obtained through a search in a database of the institution and included age; sex; presence of heart disease, cerebrovascular disease, acute/chronic kidney disease and preoperative shock. Perioperative mortality (30‐day or in‐hospital) was obtained. The risk score was applied retrospectively and expected mortality compared with the mortality that was obtained.</p></div><div><h3>Results</h3><p>89 patients were included. 49 (55%) were treated by CC and the remaining 40 (45%) by EVAR. 35% had heart disease, 12% cerebrovascular disease, kidney disease 45% and 25% preoperative shock. The average uGAS was 90.6<!--> <!-->±<!--> <!-->16.7. There were no statistically significant differences between patients undergoing EVAR or CC respecting to uGAS (<em>p</em> <!-->=<!--> <!-->0,105). Mortality at 30 days was 39.8% and was significantly lower in patients undergoing EVAR than in those undergoing CC (20% vs 55%; <em>p</em> <!-->=<!--> <!-->0.001).</p><p>Patients who died were significantly younger (70 vs. 76 years, <em>p</em> <!-->=<!--> <!-->0.031), had a higher prevalence of kidney disease (55% vs 45%; <em>p</em> <!-->=<!--> <!-->0.008), shock (59% vs 41%; <em>p</em> <!-->=<!--> <!-->0.033) and a higher uGAS (100<!--> <!-->±<!--> <!-->12,5 vs 84.6<!--> <!-->±<!--> <!-->16,3; <em>p</em> <!--><<!--> <!-->0.001). The mortality of patients with uGAS <<!--> <!-->=<!--> <!-->85 was 14.3% and patients with uGAS ><!--> <!-->85 was 56.6%.</p></div><div><h3>Conclusion</h3><p>The results demonstrate the applicability of the uGAS score for risk stratification in a National cohort of patients with RAAA that EVAR is an alternative available. However, since it was not possible to identify a cut‐off able to provide a mortality of 100% We point out that the use of scores comprises the risk of treating patients refusing that could possibly survive. Additionally, these results suggest that treatment of RAAA by EVAR is associated with better outcomes.</p></div>","PeriodicalId":30341,"journal":{"name":"Angiologia e Cirurgia Vascular","volume":"12 4","pages":"Pages 241-245"},"PeriodicalIF":0.0000,"publicationDate":"2016-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ancv.2016.04.005","citationCount":"1","resultStr":"{\"title\":\"Aplicação do Glasgow Aneurysm Score como modelo preditivo de mortalidade em doentes com rutura de aneurisma da aorta abdominal\",\"authors\":\"Rodolfo Abreu, João Monteiro e Castro, Frederico Bastos Gonçalves, Gonçalo Rodrigues, Anita Quintas, Rita Ferreira, Nelson Camacho, Maria Emília Ferreira, João Albuquerque e Castro, Luís Mota Capitão\",\"doi\":\"10.1016/j.ancv.2016.04.005\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction</h3><p>The updated Glasgow Aneurysm Score (uGAS), designed to predict mortality/morbidity perioperative after rAAA, proved to be a good predictor of short term results after treatment with conventional surgery (CC) and EVAR. The objectives were to characterize patients operated at rAAA and evaluate the applicability of uGAS in the population of a national tertiary institution with rEVAR capacity.</p></div><div><h3>Methods</h3><p>We did a retrospective analysis of patients operated in our service to rAAA between February/2011 to February/2015. The variables were obtained through a search in a database of the institution and included age; sex; presence of heart disease, cerebrovascular disease, acute/chronic kidney disease and preoperative shock. Perioperative mortality (30‐day or in‐hospital) was obtained. The risk score was applied retrospectively and expected mortality compared with the mortality that was obtained.</p></div><div><h3>Results</h3><p>89 patients were included. 49 (55%) were treated by CC and the remaining 40 (45%) by EVAR. 35% had heart disease, 12% cerebrovascular disease, kidney disease 45% and 25% preoperative shock. The average uGAS was 90.6<!--> <!-->±<!--> <!-->16.7. There were no statistically significant differences between patients undergoing EVAR or CC respecting to uGAS (<em>p</em> <!-->=<!--> <!-->0,105). Mortality at 30 days was 39.8% and was significantly lower in patients undergoing EVAR than in those undergoing CC (20% vs 55%; <em>p</em> <!-->=<!--> <!-->0.001).</p><p>Patients who died were significantly younger (70 vs. 76 years, <em>p</em> <!-->=<!--> <!-->0.031), had a higher prevalence of kidney disease (55% vs 45%; <em>p</em> <!-->=<!--> <!-->0.008), shock (59% vs 41%; <em>p</em> <!-->=<!--> <!-->0.033) and a higher uGAS (100<!--> <!-->±<!--> <!-->12,5 vs 84.6<!--> <!-->±<!--> <!-->16,3; <em>p</em> <!--><<!--> <!-->0.001). The mortality of patients with uGAS <<!--> <!-->=<!--> <!-->85 was 14.3% and patients with uGAS ><!--> <!-->85 was 56.6%.</p></div><div><h3>Conclusion</h3><p>The results demonstrate the applicability of the uGAS score for risk stratification in a National cohort of patients with RAAA that EVAR is an alternative available. However, since it was not possible to identify a cut‐off able to provide a mortality of 100% We point out that the use of scores comprises the risk of treating patients refusing that could possibly survive. Additionally, these results suggest that treatment of RAAA by EVAR is associated with better outcomes.</p></div>\",\"PeriodicalId\":30341,\"journal\":{\"name\":\"Angiologia e Cirurgia Vascular\",\"volume\":\"12 4\",\"pages\":\"Pages 241-245\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2016-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.ancv.2016.04.005\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Angiologia e Cirurgia Vascular\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1646706X16300131\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Angiologia e Cirurgia Vascular","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1646706X16300131","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
摘要
最新的格拉斯哥动脉瘤评分(uGAS)旨在预测rAAA术后围手术期的死亡率/发病率,被证明是常规手术(CC)和EVAR治疗后短期结果的良好预测指标。目的是描述在rAAA手术的患者特征,并评估具有rEVAR能力的国家高等教育机构人群中uGAS的适用性。方法回顾性分析2011年2月至2015年2月在我院行rAAA手术的患者。这些变量是通过在该机构的数据库中搜索获得的,包括年龄;性;存在心脏疾病、脑血管疾病、急性/慢性肾脏疾病和术前休克。获得围手术期死亡率(30天或住院)。回顾性应用风险评分,并将预期死亡率与获得的死亡率进行比较。结果共纳入89例患者。CC治疗49例(55%),EVAR治疗40例(45%)。35%有心脏疾病,12%有脑血管疾病,45%有肾脏疾病,25%术前休克。平均uGAS为90.6±16.7。EVAR和CC患者在uGAS方面无统计学差异(p = 0,105)。EVAR患者30天死亡率为39.8%,显著低于CC患者(20% vs 55%;p = 0.001)。死亡患者明显更年轻(70岁vs 76岁,p = 0.031),肾脏疾病患病率更高(55% vs 45%;P = 0.008),休克(59% vs 41%;p = 0.033)和更高的uGAS(100±12,5 vs 84.6±16,3;p & lt;0.001)。uGAS患者的死亡率[j];= 85的占14.3%;85为56.6%。结论uGAS评分在全国RAAA患者队列中具有危险性分层的适用性,EVAR是一种可行的替代方法。然而,由于不可能确定一个能够提供100%死亡率的临界值,我们指出,评分的使用包含了可能存活的患者拒绝治疗的风险。此外,这些结果表明,用EVAR治疗RAAA与更好的结果相关。
Aplicação do Glasgow Aneurysm Score como modelo preditivo de mortalidade em doentes com rutura de aneurisma da aorta abdominal
Introduction
The updated Glasgow Aneurysm Score (uGAS), designed to predict mortality/morbidity perioperative after rAAA, proved to be a good predictor of short term results after treatment with conventional surgery (CC) and EVAR. The objectives were to characterize patients operated at rAAA and evaluate the applicability of uGAS in the population of a national tertiary institution with rEVAR capacity.
Methods
We did a retrospective analysis of patients operated in our service to rAAA between February/2011 to February/2015. The variables were obtained through a search in a database of the institution and included age; sex; presence of heart disease, cerebrovascular disease, acute/chronic kidney disease and preoperative shock. Perioperative mortality (30‐day or in‐hospital) was obtained. The risk score was applied retrospectively and expected mortality compared with the mortality that was obtained.
Results
89 patients were included. 49 (55%) were treated by CC and the remaining 40 (45%) by EVAR. 35% had heart disease, 12% cerebrovascular disease, kidney disease 45% and 25% preoperative shock. The average uGAS was 90.6 ± 16.7. There were no statistically significant differences between patients undergoing EVAR or CC respecting to uGAS (p = 0,105). Mortality at 30 days was 39.8% and was significantly lower in patients undergoing EVAR than in those undergoing CC (20% vs 55%; p = 0.001).
Patients who died were significantly younger (70 vs. 76 years, p = 0.031), had a higher prevalence of kidney disease (55% vs 45%; p = 0.008), shock (59% vs 41%; p = 0.033) and a higher uGAS (100 ± 12,5 vs 84.6 ± 16,3; p < 0.001). The mortality of patients with uGAS < = 85 was 14.3% and patients with uGAS > 85 was 56.6%.
Conclusion
The results demonstrate the applicability of the uGAS score for risk stratification in a National cohort of patients with RAAA that EVAR is an alternative available. However, since it was not possible to identify a cut‐off able to provide a mortality of 100% We point out that the use of scores comprises the risk of treating patients refusing that could possibly survive. Additionally, these results suggest that treatment of RAAA by EVAR is associated with better outcomes.